CAS 1263774-59-9

Etrasimod arginine

Description:

Etrasimod arginine, identified by its CAS number 1263774-59-9, is a small molecule that functions primarily as a selective modulator of the sphingosine-1-phosphate (S1P) receptor. This compound is notable for its potential therapeutic applications, particularly in the treatment of autoimmune diseases and inflammatory conditions. Etrasimod arginine exhibits a favorable pharmacokinetic profile, which includes good oral bioavailability and a manageable half-life, allowing for convenient dosing regimens. The compound's mechanism of action involves the modulation of lymphocyte trafficking, leading to a reduction in the migration of immune cells to sites of inflammation. This characteristic makes it a candidate for therapies aimed at conditions such as ulcerative colitis and multiple sclerosis. Additionally, its safety profile has been evaluated in clinical trials, showing a generally tolerable side effect profile. Overall, Etrasimod arginine represents a promising avenue in the development of targeted therapies for chronic inflammatory diseases.

Delgocitinib

CAS: 1263774-59-9

Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.

Formula: C₁₆H₁₈N₆O

Purity: 99.95%

Color and Shape: Solid

Molecular weight: 310.35

Ref: TM-T15096

Delgocitinib

CAS: 1263774-59-9

Delgocitinib

Purity: ≥98%

Molecular weight: 310.35g/mol

Ref: 54-BUP12494

Delgocitinib

CAS: 1263774-59-9

Delgocitinib is a protein gene inhibitor that binds to the polymerase chain reaction (PCR) enzyme and blocks the transcription of mRNA. Delgocitinib has been shown to be effective in animal models for bowel disease, and it has also demonstrated potential as an anti-inflammatory agent. Delgocitinib binds to the catalytic subunit of DNA-dependent RNA polymerase and inhibits transcription. This drug also inhibits x-ray crystal structures of mammalian DNA gyrase and bacterial DNA topoisomerase IV, which are enzymes required for DNA replication. Delgocitinib is being investigated for its potential use in treating interferon alfa-2b resistant cancers, such as renal cell cancer, bladder cancer, and melanoma.
Delgocitinib has been shown to have acute toxicities in animals. These include decreased locomotor activity, weight loss, increased serum creatinine levels, and decreased levels of potassium in blood

Formula: C₆H₈N₆O

Purity: Min. 95%

Molecular weight: 180.17 g/mol

Ref: 3D-BD178539